Publication:
Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases.

dc.contributor.authorCatalà, A
dc.contributor.authorMuñoz-Santos, C
dc.contributor.authorGalván-Casas, C
dc.contributor.authorRoncero Riesco, M
dc.contributor.authorRevilla Nebreda, D
dc.contributor.authorSolá-Truyols, A
dc.contributor.authorGiavedoni, P
dc.contributor.authorLlamas-Velasco, M
dc.contributor.authorGonzález-Cruz, C
dc.contributor.authorCubiró, X
dc.contributor.authorRuíz-Villaverde, R
dc.contributor.authorGómez-Armayones, S
dc.contributor.authorGil Mateo, M P
dc.contributor.authorPesqué, D
dc.contributor.authorMarcantonio, O
dc.contributor.authorFernández-Nieto, D
dc.contributor.authorRomaní, J
dc.contributor.authorIglesias Pena, N
dc.contributor.authorCarnero Gonzalez, L
dc.contributor.authorTercedor-Sanchez, J
dc.contributor.authorCarretero, G
dc.contributor.authorMasat-Ticó, T
dc.contributor.authorRodríguez-Jiménez, P
dc.contributor.authorGimenez-Arnau, A M
dc.contributor.authorUtrera-Busquets, M
dc.contributor.authorVargas Laguna, E
dc.contributor.authorAngulo Menéndez, A G
dc.contributor.authorSan Juan Lasser, E
dc.contributor.authorIglesias-Sancho, M
dc.contributor.authorAlonso Naranjo, L
dc.contributor.authorHiltun, I
dc.contributor.authorCutillas Marco, E
dc.contributor.authorPolimon Olabarrieta, I
dc.contributor.authorMarinero Escobedo, S
dc.contributor.authorGarcía-Navarro, X
dc.contributor.authorCalderón Gutiérrez, M J
dc.contributor.authorBaeza-Hernández, G
dc.contributor.authorBou Camps, L
dc.contributor.authorToledo-Pastrana, T
dc.contributor.authorGuilabert, A
dc.date.accessioned2023-05-03T13:28:33Z
dc.date.available2023-05-03T13:28:33Z
dc.date.issued2021-09-21
dc.description.abstractCutaneous reactions after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are poorly characterized. To describe and classify cutaneous reactions after SARS-CoV-2 vaccination. A nationwide Spanish cross-sectional study was conducted. We included patients with cutaneous reactions within 21 days of any dose of the approved vaccines at the time of the study. After a face-to-face visit with a dermatologist, information on cutaneous reactions was collected via an online professional survey and clinical photographs were sent by email. Investigators searched for consensus on clinical patterns and classification. From 16 February to 15 May 2021, we collected 405 reactions after vaccination with the BNT162b2 (Pfizer-BioNTech; 40·2%), mRNA-1273 (Moderna; 36·3%) and AZD1222 (AstraZeneca; 23·5%) vaccines. Mean patient age was 50·7 years and 80·2% were female. Cutaneous reactions were classified as injection site ('COVID arm', 32·1%), urticaria (14·6%), morbilliform (8·9%), papulovesicular (6·4%), pityriasis rosea-like (4·9%) and purpuric (4%) reactions. Varicella zoster and herpes simplex virus reactivations accounted for 13·8% of reactions. The COVID arm was almost exclusive to women (95·4%). The most reported reactions in each vaccine group were COVID arm (mRNA-1273, Moderna, 61·9%), varicella zoster virus reactivation (BNT162b2, Pfizer-BioNTech, 17·2%) and urticaria (AZD1222, AstraZeneca, 21·1%). Most reactions to the mRNA-1273 (Moderna) vaccine were described in women (90·5%). Eighty reactions (21%) were classified as severe/very severe and 81% required treatment. Cutaneous reactions after SARS-CoV-2 vaccination are heterogeneous. Most are mild-to-moderate and self-limiting, although severe/very severe reactions are reported. Knowledge of these reactions during mass vaccination may help healthcare professionals and reassure patients.
dc.identifier.doi10.1111/bjd.20639
dc.identifier.essn1365-2133
dc.identifier.pmcPMC8444756
dc.identifier.pmid34254291
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444756/pdf
dc.identifier.unpaywallURLhttps://europepmc.org/articles/pmc8444756?pdf=render
dc.identifier.urihttp://hdl.handle.net/10668/19915
dc.issue.number1
dc.journal.titleThe British journal of dermatology
dc.journal.titleabbreviationBr J Dermatol
dc.language.isoen
dc.organizationHospital Universitario San Cecilio
dc.organizationHospital Universitario San Cecilio
dc.organizationHospital Universitario Virgen de las Nieves
dc.organizationHospital Infanta Elena
dc.page.number142-152
dc.pubmedtypeJournal Article
dc.rights.accessRightsopen access
dc.subject.mesh2019-nCoV Vaccine mRNA-1273
dc.subject.meshBNT162 Vaccine
dc.subject.meshCOVID-19
dc.subject.meshCOVID-19 Vaccines
dc.subject.meshChAdOx1 nCoV-19
dc.subject.meshCross-Sectional Studies
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshMiddle Aged
dc.subject.meshSARS-CoV-2
dc.subject.meshVaccination
dc.titleCutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number186
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC8444756.pdf
Size:
797.93 KB
Format:
Adobe Portable Document Format